GHRS
HealthcareGH Research PLC · Biotechnology · $1B
What is GH Research PLC?
GH Research PLC is a clinical-stage biopharmaceutical company based in Dublin, Ireland, focused on developing novel therapies for psychiatric and neurological disorders. Its work centers on a class of compounds that have attracted growing scientific interest in mental health treatment.
GH Research develops 5-MeO-DMT-based therapies targeting treatment-resistant depression — a condition where patients have not responded adequately to existing treatments. The company's lead candidate, GH001, is an inhalable formulation that has advanced through Phase 1 and Phase 1/2 clinical trials. Two additional candidates, GH002 (injectable) and GH003 (intranasal), remain in preclinical development. As a clinical-stage company, GH Research does not yet generate product revenue and relies on capital markets to fund its pipeline.
GH Research PLC was incorporated in 2021 and is headquartered in Dublin, Ireland.
- GH001 — inhalable 5-MeO-DMT candidate for treatment-resistant depression
- GH002 — injectable 5-MeO-DMT candidate in preclinical development
- GH003 — intranasal 5-MeO-DMT candidate in preclinical development
- Psychiatric and neurological disorder research platform
Is GHRS a Good Stock to Buy?
UQS Score rates GHRS as Poor overall, reflecting the early-stage nature of the business and the significant uncertainties that come with it.
Among the five pillars, Risk registers as the least concerning — the company carries a profile that, relative to its other weaknesses, does not stand out as the primary drag. This is not uncommon for pre-revenue biotechs that maintain lean operational structures.
Quality, Moat, and Growth all score as Weak, which is expected for a company with no approved products and no commercial revenue. Valuation is rated Elevated, meaning the current market price reflects significant future expectations that have yet to be validated by clinical outcomes.
See the full pillar breakdown and detailed financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does GHRS pay dividends?
No — GH Research PLC does not currently pay a dividend.
GH Research does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. All available capital is directed toward funding clinical trials and advancing the pipeline. Investors in GHRS are generally seeking potential appreciation from drug development milestones rather than income from distributions.
When does GHRS report earnings?
GH Research reports financial results on a quarterly cadence, consistent with US-listed equities.
As a pre-revenue company, GH Research's quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than traditional revenue and profit metrics. Pipeline updates and trial readouts tend to be the most market-moving disclosures.
For the most recent quarter's results and pipeline updates, visit GH Research's investor relations page directly.
GHRS Price History
-1.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in GH Research PLC?
Based on GH Research PLC's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
GHRS Long-term Outlook
The fundamental outlook for GHRS is shaped by binary clinical risk. With Growth and Quality both rated Weak, the company's trajectory depends almost entirely on whether its lead candidate, GH001, can demonstrate sufficient efficacy and safety in later-stage trials to attract regulatory attention. The Elevated Valuation rating suggests the market has already priced in a degree of optimism that the current clinical evidence has not yet confirmed. Risk is rated Neutral, which provides a modest counterbalance, but the overall picture remains speculative.
Growth drivers
- Potential Phase 2/3 advancement of GH001 in treatment-resistant depression
- Growing clinical and regulatory interest in psychedelic-adjacent psychiatric therapies
- Expansion of preclinical pipeline into additional neurological indications
Key risks
- Clinical trial failure or unfavorable safety data for GH001
- Elevated valuation leaves limited margin of safety if milestones are delayed
- Dependence on external financing with no product revenue to offset burn
GHRS vs Peers
GH Research operates in a competitive clinical-stage landscape alongside other small-cap biotechs pursuing novel mechanisms in psychiatry and neurology.
MBX Biosciences focuses on precision peptide therapeutics, targeting endocrine and metabolic conditions rather than psychiatric disorders.
Biohaven pursues a broader neurological pipeline including ion channel and glutamate-pathway programs, giving it a more diversified clinical profile than GHRS.
Septerna develops small-molecule drugs targeting G protein-coupled receptors, with a platform approach that differs from GHRS's compound-specific focus.
Frequently Asked Questions
What does GH Research PLC do?
GH Research is a clinical-stage biopharmaceutical company developing 5-MeO-DMT-based therapies for treatment-resistant depression and other psychiatric disorders. Its lead program, GH001, is an inhalable formulation that has completed early-phase clinical trials. Two additional candidates remain in preclinical development.
Does GHRS pay dividends?
No, GHRS does not pay a dividend. As a clinical-stage company with no product revenue, GH Research directs its capital toward funding research and clinical trials. Investors should not expect income distributions in the near term.
When does GHRS report earnings?
GH Research reports on a quarterly cadence. Because the company is pre-revenue, reports focus on cash position and pipeline progress rather than traditional financial performance. Check GH Research's investor relations page for the latest schedule and disclosures.
Is GHRS a good stock to buy?
UQS Score rates GHRS as Poor overall, driven by Weak scores across Quality, Moat, and Growth, alongside an Elevated Valuation. This profile reflects the high uncertainty inherent in clinical-stage biotech investing. Prospective investors should weigh pipeline risk carefully before making a decision.
Is GHRS overvalued?
The UQS Valuation pillar rates GHRS as Elevated, indicating the current market price embeds meaningful optimism about future clinical success. For a company with no approved products and no revenue, this leaves limited margin of safety if trial results disappoint or timelines slip.
How does GHRS compare to its competitors?
Compared to peers like Biohaven and Septerna, GH Research has a narrower, more compound-specific pipeline centered on 5-MeO-DMT. This focus could be an advantage if GH001 succeeds, but it also concentrates risk. Broader-platform peers carry different risk profiles and therapeutic targets.
What is GHRS's market cap bracket?
GHRS is classified as a small-cap stock. This places it in a segment of the market characterized by higher volatility, lower liquidity, and greater sensitivity to clinical trial outcomes compared to large- or mega-cap healthcare companies.
Who founded GH Research PLC?
GH Research PLC was incorporated in 2021. Founding and leadership details are publicly available through the company's official filings and investor relations materials, which provide the most accurate and up-to-date information on its executive team.
Is GHRS a long-term quality investment?
From a long-term quality standpoint, GHRS currently scores as Poor on the UQS composite. The Weak ratings across Quality, Moat, and Growth reflect the absence of durable competitive advantages and revenue generation at this stage. Long-term quality indicators would need to improve significantly as the pipeline matures.
What is the main competitive advantage of GH Research?
GH Research's potential advantage lies in its early-mover focus on 5-MeO-DMT formulations for treatment-resistant depression, a condition with significant unmet need. However, the UQS Moat pillar currently rates this as Weak, reflecting that no durable commercial advantage has yet been established.
What sector does GHRS belong to?
GHRS operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Its focus on psychiatric and neurological disorders places it in a subsegment that has attracted increased scientific and investor attention in recent years.
Is GHRS a growth stock or value stock?
Based on UQS pillar labels, GHRS carries a Weak Growth rating and an Elevated Valuation — a combination that fits neither the classic growth nor value profile. It is better characterized as a speculative clinical-stage bet, where returns depend on binary trial outcomes rather than compounding fundamentals.
Unlock Full GHRS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for GHRS
- ✓Access detailed financial metrics and trend data
- ✓Compare GHRS against sector peers side by side
- ✓See the complete risk and valuation breakdown
- ✓Track score changes as new data is released
- ✓Explore the full analyst view available to Pro members
Pro Analysis
GHRS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | 10.2 | 0.0 | 11.0 | 2.0 | 47.1 | 0.0 | -0.1 |
| Apr 2, 2026 | 10.3 | 0.0 | 11.0 | 2.5 | 47.1 | 0.0 | — |
GHRS — Pillar Breakdown
Quality
— 0.0/100 (25%)GH Research PLC currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 2.0/100 (20%)GH Research PLC faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 47.1/100 (15%)GH Research PLC has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)GH Research PLC appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)GH Research PLC operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GHRS.
Score Composition
Financial Data
More Stock Analysis
How is the GHRS UQS Score Calculated?
The UQS (Unified Quality Score) for GH Research PLC is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses GH Research PLC's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether GH Research PLC is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.